Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Market Closed 02-06 16:00:00 EST

25.82

+4.68

+22.14%

盘后25.37

-0.45-1.74%

19:59 EST

High25.95	Low23.97	Vol24.05M
Open24.48	D1 Closing21.14	Amplitude9.35%
Mkt Cap18.48B	Tradable Cap12.06B	Total Shares715.70M
T/O604.18M	T/O Rate5.15%	Tradable Shares467.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":25.82,"timestamp":1770411600000,"preClose":21.14,"halted":0,"volume":24052001,"hourTrading":{"tag":"盘后","latestPrice":25.37,"preClose":25.82,"latestTime":"19:59 EST","volume":213905,"amount":5521571.4225,"timestamp":1770425965245,"change":-0.45,"changeRate":-0.017428,"amplitude":0.034907},"delay":0,"changeRate":0.2213812677388836,"floatShares":467000000,"shares":715701137,"eps":-0.535859,"marketStatus":"Market Closed","change":4.68,"latestTime":"02-06 16:00:00 EST","open":24.475,"high":25.95,"low":23.973,"amount":604182488.955843,"amplitude":0.093519,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.535859,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":21.14,"preHourTrading":{"tag":"盘前","latestPrice":24.26,"preClose":21.14,"latestTime":"09:29 EST","volume":350384,"amount":8471229.413008,"timestamp":1770388199999,"change":3.12,"changeRate":0.147588,"amplitude":0.138127},"postHourTrading":{"tag":"盘后","latestPrice":25.37,"preClose":25.82,"latestTime":"19:59 EST","volume":213905,"amount":5521571.4225,"timestamp":1770425965245,"change":-0.45,"changeRate":-0.017428,"amplitude":0.034907},"volumeRatio":4.402766624508355,"impliedVol":0.513,"impliedVolPercentile":0.9323},"requestUrl":"/m/hq/s/ROIV/tweets","defaultTab":"tweets","newsList":[{"id":"2609578298","title":"Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2609578298","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609578298?lang=en_us&edition=fundamental","pubTime":"2026-02-08 11:11","pubTimestamp":1770520284,"startTime":"0","endTime":"0","summary":"Roivant Sciences (ROIV) just posted its Q3 2026 numbers with total revenue of about US$2.0 million and a basic EPS loss of US$0.38, alongside a net income loss, excluding extra items, of US$265.9 million. The company has seen quarterly revenue move from US$9.0 million in Q3 2025 to US$2.0 million in Q3 2026, while basic EPS shifted from a loss of US$0.22 to a loss of US$0.38 over the same period. This sets the scene for investors to weigh near term revenue scale against the size of ongoing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-q3-loss-of-us2659-million-tests-bullis","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-q3-loss-of-us2659-million-tests-bullis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4112","BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2609454901","title":"Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2609454901","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609454901?lang=en_us&edition=fundamental","pubTime":"2026-02-07 10:16","pubTimestamp":1770430573,"startTime":"0","endTime":"0","summary":"Roivant Sciences reported third-quarter 2025 results showing sales of US$2.00 million and a net loss of US$265.89 million, while subsidiaries Priovant and Pulmovant advanced key Phase 2 programs in rare inflammatory and pulmonary diseases.\nTogether with positive Phase 2 brepocitinib data in cutaneous sarcoidosis and rapid enrollment of mosliciguat’s PHocus trial, Roivant’s pipeline activity is increasingly central to its story despite widened losses.\nWe’ll now examine how Roivant’s progress...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-194-after-advancing-phase-2-pipe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-194-after-advancing-phase-2-pipe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2609514334","title":"Analysts Are Bullish on These Healthcare Stocks: Knight Therapeutics (KHTRF), Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609514334","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609514334?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:30","pubTimestamp":1770413419,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Knight Therapeutics (KHTRF – Research Report) and Ro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-knight-therapeutics-khtrf-roivant-sciences-roiv-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-knight-therapeutics-khtrf-roivant-sciences-roiv-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV","LU0128526141.USD","BK4112","BK4137","KHTRF","BK4581","LU0029874061.USD","BK4007","BK4585","XBI","LABU","BK4588","BK4139"],"gpt_icon":0},{"id":"2609151275","title":"BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina","url":"https://stock-news.laohu8.com/highlight/detail?id=2609151275","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609151275?lang=en_us&edition=fundamental","pubTime":"2026-02-07 02:45","pubTimestamp":1770403531,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL6N3Z20MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CG","DOCS","MAXN","ROIV","HUBG","PAA","CNX","MOH","PHM","THAR","EQT","NVR","RIOT","VG","LEN","BIIB","OFRM","PLRZ","PIPR","HOYY","NSC","KBH","NEM","TGTX","AZYY","PM","FTNT","MGM","SGP","GWW","NWL","AGMB","HL","COTY","MCHP","UAA","UI","EXE","AVY","CDE","NWSA"],"gpt_icon":1},{"id":"2609903245","title":"Roivant Sciences Up Over 17%, on Track for Record High Close -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2609903245","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609903245?lang=en_us&edition=fundamental","pubTime":"2026-02-07 00:04","pubTimestamp":1770393840,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  is currently at $24.77, up $3.63 or 17.16%. --On pace for largest percent increase since Sept. 26, 2023, when it rose 21.55%. --Up 127.43% from 52 weeks ago , when it closed at $10.89. --Up 172.77% from its 52-week closing low of $9.08 on April 8, 2025. --Traded as high as $25.49; new all-time intraday high . --Up 20.58% at today's intraday high; largest intraday percent increase since Sept. 26, 2023, when it rose as much as 25.66%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2609859779","title":"BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison","url":"https://stock-news.laohu8.com/highlight/detail?id=2609859779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609859779?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:56","pubTimestamp":1770393385,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery DennisonEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL6N3Z20YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQT","DOCS","COTY","09399","MGM","AMZZ","CDE","OFRM","NSC","NWL","PLRZ","PM","AVY","HUBG","MOH","ROIV","UAA","EXE","VG","HL","PAA","TGTX","NWSA","FTNT","HOYY","GWW","3LMI.UK","THAR","07399","CNX","MCHP","HODU","CG","BIIB","ROBN","UI","RIOT","MAXN","AMZD","09799","NEM"],"gpt_icon":1},{"id":"2609920345","title":"Roivant Sciences rises 16.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609920345","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609920345?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:06","pubTimestamp":1770390419,"startTime":"0","endTime":"0","summary":"Roivant Sciences (ROIV) is up 16.9%, or $3.57 to $24.71. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-rises-16-9-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-rises-16-9-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"1168089334","title":"Stock Track | Roivant Sciences Soars 19.68% Intraday on Positive Phase 2 Results for Skin Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1168089334","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168089334?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:56","pubTimestamp":1770389804,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) experienced a significant intraday surge of 19.68% on Friday. The sharp upward movement follows the release of encouraging clinical trial data from one of its subsidiary...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ROIV"],"gpt_icon":0},{"id":"2609259110","title":"Roivant Shares Rise on Positive Skin Disease Treatment Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2609259110","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609259110?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:16","pubTimestamp":1770387360,"startTime":"0","endTime":"0","summary":"Shares of Roivant Sciences were higher after the company released positive results from a phase-two study of its brepocitinib treatment for cutaneous sarcoidosis, a skin disease.The stock rose 14% to $24.19 in premarket trading after closing Thursday up 94% over the past 52 weeks.The company said the 45-milligram form of the drug significantly improved cutaneous sarcoidosis disease activity and that all patients receiving the dose achieved a clinically meaningful response.The drug was well tolerated with no serious adverse events and all adverse events graded mild or moderate in severity.A phase-three program for cutaneous sarcoidosis will begin this year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roivant Shares Rise on Positive Skin Disease Treatment Results","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2609591174","title":"Wall Street Set to Open Modestly Higher Friday as Tech Stocks Stabilize Following Week-Long Rout","url":"https://stock-news.laohu8.com/highlight/detail?id=2609591174","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609591174?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:11","pubTimestamp":1770387098,"startTime":"0","endTime":"0","summary":"US equities look set to open slightly higher in Friday's trading session with tech stocks rebounding modestly following a week-long rout, as stocks such as NVIDIA (NVDA), Microsoft (MSFT), and Tesla (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2092937148.SGD","LU2125909593.SGD","LU0267386448.USD","LU1582986433.USD","BK4529","LU0823414478.USD","LU0345769128.USD","IE00B775H168.HKD","IE00BLSP4452.SGD","SPXU","LU2211815571.USD","LU2430703251.USD","LU0912757837.SGD","LU1496350502.SGD","LU1852331112.SGD","LU2360106780.USD","LU2506951875.HKD","LU1582987597.SGD","SG9999014013.SGD","LU1868836757.USD","LU2023250504.SGD","GB00BDT5M118.USD","SQQQ","LU0094547139.USD","LU1551013425.SGD","IE0009356076.USD","LU1119994496.HKD","LU2244417387.USD","LU2264538146.SGD","SDOW","LU1815336760.USD","IE00BJLML261.HKD","IE0004445239.USD","LU2272731865.HKD","NVD3.UK","LU2271345857.HKD","LU1244550221.USD","LU2023251221.USD","LU0157215616.USD","SPYM","IE00BKDWB100.SGD","SNVD.UK","IE00BYQQ9H92.USD","IE00BWXC8680.SGD","LU0211327993.USD","LU0672654240.SGD","LU2362541273.HKD","LU1366333091.USD","IE00BJTD4N35.SGD","LU0210528500.USD","LU2089284900.SGD","LU2506952170.USD","LU2552382215.SGD","LU2065171311.SGD","LU1989764748.USD","LU0187121727.USD","LU0690374615.EUR","LU1181866309.USD","DIA","LU0965509283.SGD","LU0965508806.USD","IE00BQXX3D17.EUR","BK4154","LU0985320562.USD","LU2294711713.HKD","LU2362541513.USD","LU0302445910.USD","BK4139","LU1878469433.USD","MOH","BK4612","LU1316542783.SGD","LU0354030511.USD","LU0965509101.SGD","HK0000306685.HKD","LU2237443978.SGD","LU0353189680.USD","HK0000320264.USD","EHC","PSQ","TSLT","IE0003U64NQ7.SGD","SPXS","LU2089985449.USD","LU2168564222.USD","LU0353189763.USD","LU1236620750.USD","LU0234572021.USD","LU2860962120.EUR","3NVD.UK","SG9999014575.USD","LU1069344957.HKD","LU2077746001.SGD","LU1951198990.SGD","IE00BQXX3C00.GBP","LU1066051811.HKD","NVD","IE00B19Z8W00.USD","LU0198837287.USD","LU0390134368.USD","BMAY","BK4551","LU1267930813.SGD","LU1301847155.USD","LU1670628061.USD","LU2491050071.SGD","LU0072461881.USD","LU0234570918.USD","LU2506951792.HKD","BK4541","NVDU","LU1823568750.SGD","IE00B1XK9C88.USD","LU2487616109.SGD","LU2552382058.USD","LU0210536198.USD","NVDS","LU1674673428.USD","MSFW","SCHD","LU0251132253.USD","IE00B7KXQ091.USD","LU1670627923.USD","TSLQ","USJW.SI","LU2417539215.USD","LU0211328371.USD","LU2298321311.HKD","2NVD.UK","LU1064131342.USD","TSDD","LU0642271901.SGD","LU0345770993.USD","LU0342679015.USD","BK4604","LU0889566641.SGD","IVW","LU2237443382.USD","LU2461242641.AUD","LU2210150020.SGD","TESL","SGXZ23171101.USD","LU2089283258.USD","LU2168564495.EUR","SPYV","LU0444971666.USD","LU2133065610.SGD","07766","LU1429558221.USD","IE00B5949003.HKD","LU2125154778.USD","LU1974910355.USD","LU0689626769.HKD","BK4574","LU0444973449.USD","LU1032955483.USD","IE00BDCRKT87.USD","LU1366192091.USD","LU1712237335.SGD","TSLZ","LU0823421416.USD","LU0784385170.HKD","QQQY","LU2322448957.HKD","BK4605","LU0511384066.AUD","NVDY","IE00B19Z9505.USD","LU0894485498.HKD","LU2746668974.SGD","LU2087621335.USD","NVDX","LU1839511570.USD","IE000W1ABFV2.USD","BK7104","NVIW.SI","LU0323591593.USD","LU0426417589.USD","LU0053666078.USD","LU1323610961.USD","LU0823417737.USD","LU2491049909.HKD","LU0096362180.USD","LU0345770308.USD","LU1066051225.USD","LU2505996681.GBP","TSLG","LU1718418525.SGD","BK4581","LU0689472784.USD","LU2452424414.USD","LU2106854487.HKD","LU0069063385.USD","LU0942090050.USD","LU1435385759.SGD","LU1861215975.USD","LU2272731600.USD","LU2023250843.SGD","TSLP","LU1923622614.USD","LU1670711123.USD","LU0345768153.USD","LU1261432733.SGD","TSLR","LU1585245621.USD","LU0203202063.USD","LU2756315664.SGD","IE0005OL40V9.USD","LU0553294199.USD","SPDN","LU0871640123.AUD","LU1821325948.USD","LU0795875169.SGD","LU2092937221.SGD","LU1564329115.USD","LU1221951046.USD","LU1791710400.SGD","LU2125909247.SGD","IE00BFSS7M15.SGD","LU1923622291.USD","LU1153585028.USD","BK4141","LU2462157665.USD","LU2430703178.SGD","SG9999014021.USD","LU2420271590.USD","SG9999014567.USD","LU2413666699.HKD","BK4182","LU0787776722.HKD","LU1629891620.HKD","LU2242649171.HKD","BK4535","LU0289961442.SGD","LU2750360641.GBP","LU1935043023.USD","LU2456880835.USD","LU1983260115.SGD","LU1235294995.USD","LU2028103732.USD","IE00BBT3K403.USD","LU1582986359.USD","LU0124676726.USD","LU2242650005.HKD","LU0784384876.USD","LU2065171402.SGD","SG9999015945.SGD","LU1868836914.USD","LU1861127337.USD","JEPQ","LU1334329650.SGD","NVDA","BK4576","LU0314104364.USD","LU2750360997.AUD","IE00BD6J9T35.USD","BK4516","LU0738911758.USD","LU1732800096.USD","LU0097036916.USD","LU2087625088.SGD","LU0354030438.USD","LU0323240290.USD","LU1232071149.USD","LU1699723380.USD","TQQQ","LU1196500208.SGD","LU1934455863.HKD","LU0719512351.SGD","BK4577","LU1868837300.USD","LU2083900584.USD","LU0154236417.USD","BK4527","LU1059921491.USD","SG9999014039.USD","LU2592432038.USD","LU0265550946.USD","LU1280957306.USD","GB00B4QBRK32.GBP","IE0004091025.USD","SG9999015341.SGD","IE0004445015.USD","LU2213496289.HKD","LU1064927863.SGD","LU1221951129.SGD","LU0545039389.USD","USAW.SI","LU0823411888.USD","LU0690374961.EUR","LU1003077747.HKD","LU1228905540.USD","LU1868837136.USD","LU0795875086.SGD","LU2473716301.USD","LU1035775433.USD","LU1989764664.SGD","LU0784383803.USD","LU1934455277.USD","LU1116320901.HKD","IE00BMPRXN33.USD","LU1340139317.AUD","IE00B3S45H60.SGD","LU2249611893.SGD","LU0820561818.USD","SG9999004303.SGD","STLA","LU0061474705.USD","SGXZ51526630.SGD","GPIX","LU0348723411.USD","LU0879622024.SGD","LU2471134952.CNY","IE00BKPKM429.USD","LU1496350171.SGD","LU0528227936.USD","NVII","NQmain","IE00B1BXHZ80.USD","LU1188199696.SGD","IE00BSNM7G36.USD","LU2265009873.SGD","IE00BJJMRY28.SGD","LU2272731782.SGD","LU2210149790.SGD","LU2286300806.USD","LU0957808578.USD","CRSH","LU0149725797.USD","LU1035773651.USD","LU0171293334.USD","LU0095938881.EUR","TSYW.SI","LU0127658192.USD","IVV","LU2125909759.SGD","TSYY","IE00B4YYXB79.USD","LU2896262040.SGD","LU1989772923.USD","LU0683600562.USD","LU0894486033.HKD","LU0109392836.USD","LU1670710588.SGD","LU0158827948.USD","LU2471134523.USD","HK0000306701.USD","LU1267930490.SGD","IE00B5TLWC47.USD","SPY","LU2746668461.USD","IE00BK4W5M84.HKD","QQQJ","TSLW","DDM","IE000KEQY171.SGD","LU0061474960.USD","LU1815333072.USD","LU0868494617.USD","LU0210533765.USD","LU2097829019.USD","LU2111349929.HKD","LU2361044949.HKD","LU0708995401.HKD","LU2279689827.SGD","LU0640476718.USD","LU1564329628.SGD","LU1923623000.USD","BK4532","IE00B3M56506.USD","BK4543","LU0289941410.SGD","LU0256863902.USD","LU0347712357.USD","LU1032466523.USD","LU0276348264.USD","LU1564329032.USD","BK4608","LU2237443465.HKD","IE000ITXATA3.USD","LU1674673691.USD","MSFL","HK0000914686.HKD","SG9999001424.SGD","BK4598","BK4533","LU0310800379.SGD","LU1069347547.HKD","LU0792757196.USD","LU2168564149.EUR","LU0054578231.USD","LU1564329461.SGD","LU2237957811.SGD","LU2430703095.HKD","LU2764263203.CNY","TSLL","BK4528","LU1861220033.SGD","BK4550","SGXZ31699556.SGD","NVDQ","LU0823434740.USD","TSLA","LU2092627202.USD","LU1934455194.USD","IE0034235303.USD","LU2065170008.USD","LU2458330169.SGD","LU1235295455.SGD","LU1037948541.HKD","LU0079474960.USD","MNQmain","LU0557290698.USD","BK4579","IE00BMPRXR70.SGD","MSFO","LU0861579265.USD","LU2191332357.HKD","LU1066051498.USD","LU1066053197.SGD","BK4567","LU0545562505.USD","LU2357305700.SGD","LU2097344357.USD","MSFY","LU0314106906.USD","LU0426412945.USD","LU0823414551.USD","LU2360032135.SGD","LU2357125470.USD","IE00BHPRN162.USD","LU2720916845.USD","TSLI","SG9999018865.SGD","IE00BYXW3230.USD","VOO","LU0162691827.USD","LU1121112475.USD","LU0323239441.USD","LU2237443549.SGD","MSFX","LU2023250330.USD","LU1720051108.HKD","LU0106261372.USD","LU0964807845.USD","IE00BKVL7J92.USD","LU0786609619.USD","SG9999014542.SGD","SG9999015358.SGD","IE0034235188.USD","LU1992135399.USD","LU0823421333.USD","LU2237438978.USD","VTI","IE00BZ1G4Q59.USD","LU0788109477.HKD","LU2458330243.SGD","LU1506573853.SGD","LU2095319765.USD","SG9999014906.USD","LU2360108059.USD","BK4504","LU1642822529.SGD","LU0345774631.USD","DOG","LU0949170772.SGD","IE00BQXX3F31.USD","IE0004086264.USD","LU0265550359.USD","BK4592","LU2602419157.SGD","IE0001KFT4U8.USD","SG9999000418.SGD","LU1989763005.USD","QID","LU1791710582.SGD","IE00BK4W5L77.USD","IVOO","LU2326559502.SGD","LU1935042215.USD","SG9999015986.USD","HIBL","LU2404859667.USD","LU1992135472.HKD","LU2931357623.SGD","LU1043141123.HKD","LU2125909916.SGD","SSO","LU0057025933.USD","LU0494093205.USD","IE00B19Z8X17.USD","LU2552382132.HKD","MYMmain","LU0109391861.USD","LU1244550494.USD","DIPS","LU1145028129.USD","QYLG","LU2381873111.SGD","SG9999014559.SGD","BK4538","BK4585","LU1721428933.USD","LU2505996509.AUD","LU1720051017.SGD","IE0009G5SDU7.USD","LU1242518857.USD","BK4549","LU0029864427.USD","LU1691799644.USD","LU1803068979.SGD","LU1778281490.HKD","LU1861559042.SGD","HK0000320223.HKD","LU2491050154.USD","LU2413666426.HKD","SG9999015978.USD","LU1935042488.USD","UDOW","LU2506951958.HKD","IE00BJTD4V19.USD","LU0316494557.USD","LU0823417653.USD","BK4525","NVDW","LU2506952097.USD","LU2065169927.USD","LU2125154935.USD","LU0077335932.USD","SG9999002224.SGD","SG9999018857.SGD","LU0882574139.USD","LU2463028550.USD","LU2360107168.USD","LU1633808545.USD","DJX","LU2764262908.HKD","LU1548497426.USD","LU2403377893.USD","LU1814569148.SGD","LU1267930573.SGD","BK4185","LU0868494708.USD","LU1861558580.USD","LU2054465674.USD","LU0289960550.SGD","LU1914381329.SGD","LU2275660780.HKD","SG9999015952.SGD","VOOV","LU0289739343.SGD","LU2063271972.USD","LU0965509010.AUD","LU0889565833.HKD","BK4503","SG9999014005.SGD","LU2097344431.USD","LU1951200564.SGD","BK4099","LU0175139822.USD","IE000YTNTUN2.SGD","LU0128525929.USD","LU2237957902.USD","HK0000914660.USD","LU0048584097.USD","SPLV","SG9999002232.USD","IE00B4JS1V06.HKD","BK4548","LU1244550577.SGD","LU2361044865.SGD","LU2168563687.JPY","GB00B4LPDJ14.GBP","LU1037948897.HKD","LU2471134796.USD","LU2237443622.USD","LU2756315318.SGD","IE00BN8TJ469.HKD","LU0274383776.USD","LU1267930730.SGD","LU0320765059.SGD","QLD","LU0082616367.USD","LU0979878070.USD","SDS","LU0417517546.SGD","BK4511","TSLO","LU1236620834.HKD","TSLY","TSLS","PI","LU0096364046.USD","LU2250418816.HKD","LU0256863811.USD","IE00BFSS8Q28.SGD","LU0345768740.USD","SG9999014898.SGD","SH","LU0072462426.USD","LU0476273544.USD","TSL","LU0957791311.USD","LU0203201768.USD","LU1988902786.USD","LU0345774391.USD","LU0823434583.USD","LU2108987350.USD","LU0266013472.USD","LU0061475181.USD","DXD","LU1116320737.USD","LU1868836591.USD","LU0724617625.USD","LU0238689110.USD","LU2237443895.HKD","LU0960925559.SGD","IE00B3SWFQ91.USD","MSFD","SPXL","LU1582987324.SGD","LU0466842654.USD","LU1935042991.SGD","SG9999014880.SGD","SG9999014914.USD","LU1043141396.HKD","BK4554","BK4555","LU1242518931.SGD","SGXZ99366536.SGD","BK4534","IE00BZ199S13.USD","LU0726765562.USD","LU1228905037.USD","LU2322448791.USD","LU2361045086.USD","LU0708994859.HKD","LU2471134879.HKD","BK4097","MSFT","IE0034235295.USD","LU2433249047.HKD","LU1623119135.USD","NVDG","IE00BLSP4239.USD","LU2247934214.USD","LU2148611432.USD","LU1551013342.USD","LU1935043536.SGD","LU1804176565.USD","LU0472753341.HKD","LU1127390331.HKD","LU2347655156.SGD","IE00B775SV38.USD","IE00BN29S564.USD","BK4007","LU2347655073.USD","LU0820562030.AUD","LU1803068623.USD","LU2764263039.SGD","LU0820561909.HKD","IE00BDRTCR15.USD","LU0011850046.USD","LU2168564065.EUR","LU1074936037.SGD","LU1430594728.SGD","LU0456855351.SGD","LU2290526834.HKD","LU2236285917.USD","LU0215105999.USD","LU0308772762.SGD","XDTE","IE00BFXG0V08.USD","LU1670710661.SGD","SG9999017495.SGD","NVD2.UK","LU2543165471.USD","BK4588","BK4614","QYLD","LU2362540622.SGD","LU2404859741.USD","LU0225283273.USD","LU1670711040.USD","SGXZ81514606.USD","LU0345769631.USD","LU0080751232.USD","LU1989773731.SGD","NVDS.UK","LU0006306889.USD","LU0056508442.USD","LU0107464264.USD","LU0170899867.USD","LU0757359368.USD","LU0757359954.USD","LU0784385840.USD","BK4587","LU0950375773.USD","LU0158827781.USD","ROIV","BK4566","LU1084165304.USD","LU0312595415.SGD","LU1571399168.USD","LU0310799852.SGD","IE00BMPRXQ63.HKD","GPIQ","QQQE","LU2041044095.USD","LU0949170426.SGD","LU0943347566.SGD","LU1046421795.USD","LU0070217475.USD","LU0994945656.USD","LU1917777945.USD","SG9999001077.SGD","IE00BJJMRX11.SGD","LU1989772840.SGD","LU0661504455.SGD","TSII","LU1697837992.HKD","LU1732799900.SGD","NVDD","LU0081259029.USD"],"gpt_icon":1},{"id":"2609950605","title":"BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609950605","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609950605?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:11","pubTimestamp":1770383476,"startTime":"0","endTime":"0","summary":"BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)Feb 6 (Reuters) - Priovant:PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SAR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nTUA1GHWNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"2609595272","title":"Priovant's Brepocitinib Shows Skin Disease Improvement in Phase 2 Study; Pulmovant Completes Lung Disease Trial Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2609595272","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609595272?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:07","pubTimestamp":1770383220,"startTime":"0","endTime":"0","summary":"Roivant Sciences' (ROIV) unit Priovant Therapeutics said Friday the phase 2 study of its experimental drug, brepocitinib, showed improvement in cutaneous sarcoidosis disease activity at higher doses, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2609595373","title":"Shares of Roivant up 15.8% Premarket After Experimental Drug Shows Benefit in Rare Skin Disease, Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2609595373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609595373?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:58","pubTimestamp":1770382691,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL6N3Z20SU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2609859351","title":"Roivant Sciences posts nine-month revenue of USD 5.74 million, down 73 percent","url":"https://stock-news.laohu8.com/highlight/detail?id=2609859351","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609859351?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:32","pubTimestamp":1770381159,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. reported its financial results for the nine months ended December 31, 2025. Total revenue for the period was USD 5.74 million. The company recorded a net loss attributable to shareholders of USD 602.77 million for the nine-month period. Research and development expenses totaled USD 482.87 million, while cost of revenues amounted to USD 0.97 million. Income tax expense was USD 34.98 million for the same period. For the third quarter, Roivant Sciences reported revenue of USD 5.74 million and a net loss attributable to shareholders of USD 265.89 million. During the period, Roivant Sciences continued to advance its pipeline, which includes brepocitinib, a small molecule inhibitor of TYK2 and JAK1 being developed for dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis. The pipeline also features IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn and being developed for several IgG-mediated autoimmune indications. The company reaff","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL29q63X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"2609526593","title":"S&P 500 Futures Climb In Premarket Trading; Doximity, Stellantis Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2609526593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609526593?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:31","pubTimestamp":1770381060,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, Encompass Health Corp.  was up 16.6% in pre-market trading, and Bloom Energy Corp.  was up 12.4%.Roblox Corp. , Reddit Inc. , and Roivant Sciences Ltd.  were all posting gains of at least 9%. In early trading, Doximity Inc.  and Stellantis N.V.  had posted declines, falling 30.7% and 27.0%, respectively.Meanwhile S&P 500 futures were up 0.54%, with futures for the Dow Jones Industrial Average rising 0.50%. The Cboe Volatility Index futures were up 11.88%.In commodities news, Brent crude oil futures were down 0.64%, and gold futures were up 0.39%. Bitcoin climbed 4.27% to $66,312.In the previous regular trading session, the S&P 500 and the Dow were down 1.23% and 1.20%, respectively. Stocks in Asia were mixed overnight, with Japan's NIKKEI 225 Index up 0.81% and China's Shanghai Composite Index down 0.25%.In afternoon trading, stocks in Europ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2294711713.HKD","LU0444973449.USD","BK4554","LU0823414551.USD","SPDN","ROIV","SPXU","RDTL","IE0001KFT4U8.USD","BK4551","SPYV","LU2357125470.USD","LU0054578231.USD","LU0348723411.USD","UPRO","SPXL","BK4185","LU1861558580.USD","BK4099","IVV","VTI","LU0957808578.USD","LU2237957811.SGD","LU2249611893.SGD","SGXZ23171101.USD","SSO","SH","SPYM","SDS","LU1861559042.SGD","SPLV","BK4550","BK4167","DOCS","LU0444971666.USD","BK4139","BK4007","LU2506951792.HKD","BK4565","BK4535","BK4598","LU1983260115.SGD","STLA","BK4534","OEX","SG9999004303.SGD","BK4504","IVW","LU1064927863.SGD","LU0476273544.USD","BK4559","LU2264538146.SGD","LU1815336760.USD","BK4547","BK4182","LU2360107168.USD","LU0786609619.USD","BK4588","BK4613","VOOV","LU1642822529.SGD","MESmain","XDTE","LU2290526834.HKD","BK4581","BK4085","SPXS","BK4585","LU2543165471.USD","LU1861215975.USD","LU1861220033.SGD","BK4077","BMAY","HIBL","LU2237957902.USD","ESmain","GPIX","LU0823414478.USD","OEF","BK4539","EHC","BK4541","IVOO","LU1064131342.USD","LU1988902786.USD"],"gpt_icon":1},{"id":"2609598448","title":"BUZZ-Roivant shares rise as experimental drug shows benefit in rare skin disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2609598448","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609598448?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:18","pubTimestamp":1770380334,"startTime":"0","endTime":"0","summary":"BUZZ-Roivant shares rise as experimental drug shows benefit in rare skin disease** Shares of developer Roivant ROIV.O up 8.8% at $23 premarket ** Co says in a midstage trial, brepocitinib improved symptoms of cutaneous sarcoidosis — a rare skin disease caused by inflammation that forms painful lumps under the skin** Higher dose improved disease activity scores by about 22 points over 16 weeks vs about 1 point for placebo, co says** More than half of treated patients reached functional remission, per investigator Dr. Misha Rosenbach** Co to start late-stage trial in 2026 after talks with U.S. FDA** Shares up ~83% in 2025  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL4N3Z21AA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2609598134","title":"Roivant swings to Q3 loss as revenue drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2609598134","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609598134?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:12","pubTimestamp":1770379936,"startTime":"0","endTime":"0","summary":"Roivant swings to Q3 loss as revenue dropsOverviewBiopharmaceutical firm's Q3 revenue drops to $2 mln from $9 mln yr-agoPosts Q4 net loss vs profit in year-ago quarterRoivant reported $4.5 bln in cash","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL1N3Z20K4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"2609598979","title":"Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q3 Net Loss $0.38 a Share, vs. FactSet Est of $0.30 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2609598979","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609598979?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:09","pubTimestamp":1770379794,"startTime":"0","endTime":"0","summary":"Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q3 Net Loss $0.38 a Share, vs. FactSet Est of $0.30 Loss","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ROIV"],"gpt_icon":0},{"id":"1130252803","title":"Stock Track | Roivant Sciences Soars 9.93% in Pre-market on Positive Phase 2 Results for Brepocitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1130252803","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130252803?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:09","pubTimestamp":1770379741,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) experienced a significant pre-market surge of 9.93% on Friday. The sharp upward movement follows the release of encouraging clinical trial data from one of its subsidiary...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ROIV"],"gpt_icon":0},{"id":"2609598617","title":"Immunovant Q3 net loss smaller than expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2609598617","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609598617?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:08","pubTimestamp":1770379698,"startTime":"0","endTime":"0","summary":"Immunovant Q3 net loss smaller than expectedOverviewClinical-stage immunology firm's Q3 net loss beat analyst expectationsCompany completed $550 mln financing, extending cash runway for IMVT-1402 laun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL1N3Z20K1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","IMVT","BK4585","BK4588","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":0.1943},{"period":"1month","weight":0.1747},{"period":"3month","weight":0.2522},{"period":"6month","weight":1.2472},{"period":"1year","weight":1.3753},{"period":"ytd","weight":0.1899}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.028555},{"month":3,"riseRate":0,"avgChangeRate":-0.096551},{"month":4,"riseRate":0.8,"avgChangeRate":0.019894},{"month":5,"riseRate":0.4,"avgChangeRate":0.032328},{"month":6,"riseRate":0.8,"avgChangeRate":0.015077},{"month":7,"riseRate":0.8,"avgChangeRate":0.040575},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}